featured
Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for Treating Pemphigus Vulgaris
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris
JAMA Dermatol 2022 Jul 27;[EPub Ahead of Print], MKY Chen, R Vissapragada, N Bulamu, M Gupta, V Werth, DF SebaratnamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.